Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

STEM CELLS

Muscling toward therapy with ERBB3 and NGFR

To overcome the finite supply of muscle stem cells available for cell therapy, a study now describes a strategy for obtaining an unlimited source of myogenic progenitors derived from human pluripotent cells. Two neuronal cell surface receptors facilitate the selection of a population with enhanced regenerative potential.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Neuronal markers facilitate isolation of myogenic progenitors derived from hiPSCs.

References

  1. Blau, H. M., Cosgrove, B. D. & Ho, A. T. Nat. Med. 21, 854–862 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Cosgrove, B. D. et al. Nat. Med. 20, 255–264 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Gilbert, P. M. et al. Science 329, 1078–1081 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Quarta, M. et al. Nat. Biotechnol. 34, 752–759 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Castiglioni, A. et al. Stem Cell Rep. 2, 92–106 (2014).

    Article  CAS  Google Scholar 

  6. Charville, G. W. et al. Stem Cell Rep. 5, 621–632 (2015).

    Article  CAS  Google Scholar 

  7. Xu, X. et al. Stem Cell Rep. 5, 419–434 (2015).

    Article  CAS  Google Scholar 

  8. Hicks, M. R. et al. Nat. Cell Biol. https://doi.org/10.1038/s41556-017-0010-2 (2017).

  9. Chal, J. et al. Nat. Biotechnol. 33, 962–969 (2015).

    Article  CAS  PubMed  Google Scholar 

  10. Shelton, M. et al. Stem Cell Rep. 3, 516–529 (2014).

    Article  CAS  Google Scholar 

  11. Wehrman, T. S. et al. Proc. Natl Acad. Sci. USA 103, 19063–19068 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Tomellini, E., Lagadec, C., Polakowska, R. & Le Bourhis, X. Cell. Mol. Life Sci. 71, 2467–2481 (2014).

    Article  CAS  PubMed  Google Scholar 

  13. Ho, A. T. V. et al. Dev. Cell 21, 273–287 (2011).

    Article  CAS  PubMed  Google Scholar 

  14. Deponti, D. et al. Mol. Biol. Cell 20, 3620–3627 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Golding, J. P., Calderbank, E., Partridge, T. A. & Beauchamp, J. R. Exp. Cell Res. 313, 341–356 (2007).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Helen M. Blau.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ho, A.T.V., Blau, H.M. Muscling toward therapy with ERBB3 and NGFR. Nat Cell Biol 20, 6–7 (2018). https://doi.org/10.1038/s41556-017-0015-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41556-017-0015-x

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research